Beneficial Effects of ILimosilactobacillus fermentum/I in the DCA Experimental Model of Irritable Bowel Syndrome in Rats

Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological co...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2022-12, Vol.15 (1)
Main Authors: Rodríguez-Sojo, María Jesús, Garcia-Garcia, Jorge, Ruiz-Malagón, Antonio Jesús, Diez-Echave, Patricia, Hidalgo-García, Laura, Molina-Tijeras, José Alberto, González-Lozano, Elena, López-Escanez, Laura, Rodríguez-Cabezas, María Elena, Rodríguez-Sánchez, Maria José, Rodríguez-Nogales, Alba, Mediavilla, Cristina, Galvez, Julio
Format: Article
Language:English
Subjects:
Diet therapy
Health aspects
Irritable bowel syndrome
Lactobacillus
Physiological aspects
Probiotics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716 in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum CECT5716 (10[sup.9] CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu15010024